Month: June 2021

Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer’s Association International Conference

Posted on by Admin


Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer’s Association International Conference

 

Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease

MIAMI, June 24, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for aging-related and chronic disease, announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion for patients with mild Alzheimer’s disease has been accepted for a Developing Topics poster presentation at the 2021 Annual Alzheimer’s Association International Conference, being held July 26-30, 2021 in Denver, CO and online.

The abstract is titled “Safety and Efficacy of Lomecel-B in Patients with Mild Alzheimer’s Disease: Results of a Double-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial.” This 33 subject study was supported by two competitive Part the Cloud Challenge on Neuroinflammation grants from the Alzheimer’s Association. The previously announced results can be found on the “News and Events” page in the Investors section of Longeveron’s website at investors.longeveron.com.

“We are extremely pleased that the Alzheimer’s Association has recognized our trial and data by giving us this opportunity to present the findings in poster presentation form at the prestigious AAIC,” said Dan Gincel, Ph.D., Senior Vice President of Strategic Collaborations & Scientific Affairs at Longeveron. “The trial met its primary endpoint of demonstrating safety and feasibility, and importantly, no Alzheimer’s Related Imaging Abnormalities (ARIA), after infusion with Lomecel-B. Furthermore, we were thrilled to observe that treatment with low-dose Lomecel-B slowed cognitive decline compared to the placebo group as measured by the Mini Mental State Exam (MMSE) score. As a result, we look forward to advancing Lomecel-B into a Phase 2 clinical trial in the second half of 2021.”

Information about the Annual Alzheimer’s Association International Conference can be found at www.alz.org/aaic/overview.asp.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements that reflect management’s current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Moreover, forward-looking statements in this release include, but are not limited to, statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates, our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact:

Brendan Payne
Stern Investor Relations, Inc.
Office Direct: 212-698-8695 |Office Main: 212-362-1200
brendan.payne@sternir.com | www.sternir.com

Source: Longeveron Inc

Esports Entertainment Group Partners with Indian Gaming Esports Association and Spectrum Gaming Capital to Bring Esports to Tribal Nations and Casinos

Posted on by Admin

 


Esports Entertainment Group Partners with Indian Gaming Esports Association and Spectrum Gaming Capital to Bring Esports to Tribal Nations and Casinos

 

Newark, New Jersey–(Newsfile Corp. – June 24, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW), an esports entertainment and online gambling company, signed a partnership agreement with the Indian Gaming Esports Association (“iGEA”), the first-ever tribal esports organization to advance esports adoption among tribal nations and casinos; and with Spectrum Gaming Capital, international consultants and investment bankers.

Under the terms of the agreement, Esports Entertainment Group will be the exclusive provider of esports technology and services to iGEA as it seeks to integrate a full suite of B2C and B2B esports services to tribes and tribal casinos.

“Indian Gaming has historically been a key driver of industry evolution, and with our entrance into esports, we plan to keep our nations at the forefront of gaming’s newest trends,” said Oneida Nation’s Ernest Stevens III, CEO of iGEA. “Esports Entertainment Group has the vision, expertise, and, most importantly, the assets for a turnkey business operation and future-minded strategy that aligns with the best interests of tribes and tribal casinos; no need to re-invent the wheel. Additionally, Spectrum Gaming Capital has the relationships and strategic capabilities to help drive this new venture to real success.”

“This is a tremendous opportunity to pioneer a massive untapped market,” said Grant Johnson, CEO of Esports Entertainment Group. “We look forward to providing iGEA the tools and technology necessary to execute on their vision of building and leading the esports ecosystem for tribal nations.” Robert Heller, CEO of Spectrum Gaming Capital, added: “The entire Spectrum Gaming Group of Companies see the potential for iGEA to create a tribal-centric esports organization that will foster members’ opportunities to compete nationally and globally, and tie into tribal casino operations in those states where betting on esports is permitted by law.

About iGEA

IGEA is being formed as a non-profit corporation with the intent to organize and promote tribal participation and competition in esports. Analogous to the International Olympics Committee, iGEA will support formation and training of tribal teams and leagues to compete regionally and nationally as well as internationally. IGEA will foster game integrity, in part, to enable regulated betting, where allowed, that will increase fan engagement and sponsorships to provide funding to foster player growth and tribal identity.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

About Spectrum Gaming Capital

Spectrum Gaming Capital offers M&A and investment-banking advisory services to the global gaming and gambling industries, working with developers of casinos to help them organize, arrange strategic partnerships and raise capital; providing mid-market M&A and financing services, as well as a variety of advisory services including valuation, expert witness, due diligence, and negotiation support. We are part of the Spectrum Gaming Group of Companies which includes specialty practices in esports, sports wagering, igaming, lotteries, anti-money laundering, economic analysis and government policy, and is a global leader in providing governments with services related to licensing investigations (“NFC Global”), and data (“Spectrumetrix”), as well as geographic specialty groups focused on Asia and Latin America.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com

Media & Investor Relations Inquiries – Jeff@esportsentertainmentgroup.com
info@spectrumgamingcapital.com

Release – Esports Entertainment Group Partners with Indian Gaming Esports Association and Spectrum Gaming Capital

Posted on by Admin

 


Esports Entertainment Group Partners with Indian Gaming Esports Association and Spectrum Gaming Capital to Bring Esports to Tribal Nations and Casinos

 

Newark, New Jersey–(Newsfile Corp. – June 24, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW), an esports entertainment and online gambling company, signed a partnership agreement with the Indian Gaming Esports Association (“iGEA”), the first-ever tribal esports organization to advance esports adoption among tribal nations and casinos; and with Spectrum Gaming Capital, international consultants and investment bankers.

Under the terms of the agreement, Esports Entertainment Group will be the exclusive provider of esports technology and services to iGEA as it seeks to integrate a full suite of B2C and B2B esports services to tribes and tribal casinos.

“Indian Gaming has historically been a key driver of industry evolution, and with our entrance into esports, we plan to keep our nations at the forefront of gaming’s newest trends,” said Oneida Nation’s Ernest Stevens III, CEO of iGEA. “Esports Entertainment Group has the vision, expertise, and, most importantly, the assets for a turnkey business operation and future-minded strategy that aligns with the best interests of tribes and tribal casinos; no need to re-invent the wheel. Additionally, Spectrum Gaming Capital has the relationships and strategic capabilities to help drive this new venture to real success.”

“This is a tremendous opportunity to pioneer a massive untapped market,” said Grant Johnson, CEO of Esports Entertainment Group. “We look forward to providing iGEA the tools and technology necessary to execute on their vision of building and leading the esports ecosystem for tribal nations.” Robert Heller, CEO of Spectrum Gaming Capital, added: “The entire Spectrum Gaming Group of Companies see the potential for iGEA to create a tribal-centric esports organization that will foster members’ opportunities to compete nationally and globally, and tie into tribal casino operations in those states where betting on esports is permitted by law.

About iGEA

IGEA is being formed as a non-profit corporation with the intent to organize and promote tribal participation and competition in esports. Analogous to the International Olympics Committee, iGEA will support formation and training of tribal teams and leagues to compete regionally and nationally as well as internationally. IGEA will foster game integrity, in part, to enable regulated betting, where allowed, that will increase fan engagement and sponsorships to provide funding to foster player growth and tribal identity.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

About Spectrum Gaming Capital

Spectrum Gaming Capital offers M&A and investment-banking advisory services to the global gaming and gambling industries, working with developers of casinos to help them organize, arrange strategic partnerships and raise capital; providing mid-market M&A and financing services, as well as a variety of advisory services including valuation, expert witness, due diligence, and negotiation support. We are part of the Spectrum Gaming Group of Companies which includes specialty practices in esports, sports wagering, igaming, lotteries, anti-money laundering, economic analysis and government policy, and is a global leader in providing governments with services related to licensing investigations (“NFC Global”), and data (“Spectrumetrix”), as well as geographic specialty groups focused on Asia and Latin America.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com

Media & Investor Relations Inquiries – Jeff@esportsentertainmentgroup.com
info@spectrumgamingcapital.com

Release – enCore Energy Announces Positive Preliminary Economic Assessment (PEA) Results

Posted on by Admin


enCore Energy Announces Positive Preliminary Economic Assessment (PEA) Results and combined, N.I. 43-101 Technical Report for its Juan Tafoya-Marquez Project, New Mexico

 

CORPUS CHRISTI, Texas, June 24, 2021 /PRNewswire/ – enCore Energy Corp. (TSXV: EU) (OTCQB: ENCUF) (the “Company” or “enCore“) is pleased to announce the results of a Preliminary Economic Assessment (“PEA”) for the company’s recently consolidated Juan Tafoya and Marquez projects located in the Grant’s Uranium District in northwest New Mexico.  This is the first PEA for the projects as this is the only time in recent history that the two contiguous mineralized properties have been held under the same company.  The PEA was constructed based on a combined and updated NI 43-101 Technical Report using an Indicated resource of 7.1 million tons at a grade of 0.127% eU3O8 for a total of 18.1 million pounds of U3O8.

The PEA reports the Net Present Value (“NPV”) for the project that ranges from $20.9 million using $60.00 per pound of yellowcake (U3O8) to $71.2 million using  $70.00 per pound of yellowcake with internal rate of returns (“IRR”) ranging from 17% to 39% with corresponding yellowcake prices; these scenarios are pre-tax and assume a 7% discount rate. The break-even price of production is estimated to be $56.00 per pound. 

 “This initial PEA enables enCore to illustrate the economic opportunities of the combined Juan Tafoya and Marquez deposits which have been consolidated with the Westwater Resources transaction completed at year end 2020.  This report assumed conventional underground operation and recovery through a newly constructed conventional mill, though the authors did acknowledge that further research may prove the property amenable to either in-situ recovery (“ISR”) or heap leach processing; either of which would have a positive material impact on the economic conclusions of the current PEA.” said Paul Goranson, Chief Executive Officer. “This study points to the economic importance of our conventional assets in New Mexico, with further work it may well be determined that some, or conceivably most, of the uranium at Juan Tafoya-Marquez might be amenable to lower cost recovery options including ISR or heap leaching.”

The PEA evaluated the economics of mining at Juan Tafoya-Marquez through underground mining and on-site processing (milling) to produce yellowcake. The study has an effective date of June 9, 2021, and was prepared by Douglas L. Beahm, P.E, P.G., of BRS Inc. in cooperation with Terence P. McNulty, P.E., PhD, of McNulty and Associates.

PEA Summary Mine Plan and Operating Assumptions

Total Tons mined

6,033,000

Total Tons Waste mined

1,392,000

Total Tons of Resource mined

4,641,000

Total Pounds Yellowcake ( U3O8  ) Contained

12,184,000

Average Diluted Grade %  U3O8

0.188%

Total Pounds  U3O8 Recovered @ 95% recovery

11,575,000

Life of Mine

15 years

PEA Summary Capital and Operating Costs

Initial Capital Costs (including contingency)

Mine Direct Capital

$42,110,000

Mill and Tailings Capital

$37,200,000

Total LOM Capital Costs

$79,310,000

Life of Mine Cost Summary

Cost Center

Total Cost US$ (x1,000)*

Cost per Pound Recovered US$

OPEX Mine

$308,000

$26.62

OPEX Mill

$184,000

$15.90

Decommissioning and Reclamation

$13,000

$1.11

Taxes and Royalties

$53,000

$4.55

TOTAL OPEX (LOM)

$558,000

$48.10*

*rounded

PEA Summary Economics at $60.00/lb. Yellowcake (U3O8)

Pre-tax and Royalty NPV at 7%

$20,595,000

Pre-tax and Royalty IRR

17%

Post Tax and Royalty NPV at 5%

$18,473,000

Post Tax and Royalty IRR

16%

Post Tax payback

5.0 years

Total LOM Revenue

$694,474,000

Total LOM Direct Costs

$523,699,000

Total LOM Royalties

$33,566,000

Total LOM Taxes

$3,225,000

Total cash Flow after taxes and royalties

$54,674,000

Cash Cost ($/lb.  U3O8)

$42.53

The base case summarized above assumes the owner will purchase all mining equipment.  The base case assumes mining and milling at an average rate of 1000 tons per day year-round

Sensitivities

U3O8 Price US$/lb

$60

$65

$70

Pre-Tax NPV 5% $000

$20,914

$50,970

$71,199

Pre-Tax IRR

17%

30%

39%

Mineral Resources

The mineral resources used in this PEA include Indicated mineral resources estimated by Douglas Beahm.  The resources are found in two different stacked sands currently identified on the Juan Tafoya-Marquez property. Mineralization occurs in a third upper sand but is insufficiently defined to be included in this report.  The in-situ estimates used electronic logs from 926 drill holes and over 575,809 meters of drilling. 

Indicated Mineral Resources

Indicated Mineral Resources


Minimum 0.60 GT

TONS

%eU3O8

Pounds

C Sand

1,426,355

0.156

4,455,706

D Sand

5,685,244

0.120

13,678,258

TOTAL

7,111,599

0.127

18,133,964

ROUNDED TOTAL (x 1,000)

7,100

0.127

18,100

Disclosure

The PEA is only summarized in this press release as an initial high-level review of the project the complete detailed report will be filed on SEDAR within 30 days of this press release.  The PEA is preliminary in nature.  There is no guarantee that the project economics described in this report will be achieved.

Qualified Persons

The independent qualified persons responsible for preparing the Juan Tafoya-Marquez Preliminary Economic Assessment are Douglas L. Beahm, P.E., P.G., of BRS Inc. and Terence P. McNulty, of McNulty and Associates.

Douglas H. Underhill, PhD, CPG, enCore’s Chief Geologist, is the Company’s designated Qualified Person (QP) for this news release within the meaning of NI 43-101 and has reviewed and validated that the information contained in the release is consistent with that provided by the QP’s responsible for the PEA.

About enCore Energy Corp.
enCore Energy Corp. is a U.S. domestic uranium developer focused on becoming a leading in-situ recovery (ISR) uranium producer. The Company is led by a team of industry experts with extensive knowledge and experience in the development and operations of in situ recovery uranium operations. enCore Energy’s opportunities are created from the Company’s transformational acquisition of its two South Texas production facilities, the changing global uranium supply/demand outlook and opportunities for industry consolidation.  These short-term opportunities are augmented by our strong long term commitment to working with local indigenous communities in New Mexico where the company holds significant uranium resources including the NI 43-101 resources at the partially permitted Crownpoint-Hosta Butte property and the NI-43-101 resources at the Juan Tafoya-Marquez property.

www.encoreenergycorp.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This press release contains projections and forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.

SOURCE enCore Energy Corp.

Index Funds Still May Fall Apart over Time

Posted on by Admin 

Image Credit: dfirecop (Flickr)


In Nine Years, Nearly All Boomers Will Have Retired, Is This Good for Stock Pickers?

 

Individual investors have it better than ever. Better in terms of available investment types. Better in terms of charting software. Better in terms of trading on the go. Better access to information. And, far lower costs.   But, with all of this, some people are still investing like it’s 1971.

 

Are Index Funds More Prudent Individual Stocks?

In 1971, William Fouse and John McQuown of Wells Fargo started the first indexed fund. John Bogle used this as a foundation to build The Vanguard Group, the mutual fund provider. Mutual funds based on an index made a good deal of sense. The original idea behind indexing is that the larger group of active traders and professional investors would dictate how the market behaves, and that a small number of passive investors (index funds) would simply go along for the ride. Back then, it was a more diversified ride with professionals generating direction.

The idea was a good one; investors could avoid paying a $200 or more commission to a broker to buy a stock and could get market exposure along with diversification in ways a $200 commission had been preventing.

The mutual fund industry expanded, and from it grew many active funds. In the late 70’s the Revenue act of 1978 included a section 401(k), this allowed for deferred compensation. From it grew the entire institution of 401(k)s and brought the concept of mutual funds into many more homes than would have ever considered them.

While all types of funds quickly were developed, index funds were and remain the popular option for mutual fund investors, whether pre-tax retirement or part of an after-tax savings portfolio. 

In 1990 Exchange Traded Funds or ETFs were brought to market as a way to provide individuals access to passive, indexed funds at a much lower cost than mutual funds. The assets of these funds swelled. As they swelled, the underlying stocks did better; as they did better, more investors, particularly those that are in or near retirement, got on board.

 

Does this Create a Problem?

Not all concerns become problems, but this concern is easy to understand. At present, the largest pool of investments sits with baby boomers who have a large portion of their money in the indexed funds that have served them well. They are in or approaching retirement which is when they move from accumulation of assets to distribution for living costs. They do this by selling off their portfolios slowly, portfolios including the indexed funds. As these funds are sold off, the stocks being held are in less demand.

 

“The simple theses and the models that get people into sectors, factors, indexes, or ETFs and mutual funds mimicking those strategies – these do not require the security-level analysis that is required for true price discovery,” Michael Burry, Bloomberg Interview, September
2019

 

The second largest group of investors in terms of bodies, not wealth, are their children and grandchildren. This group began to become aware of the stock market during the boom years from 2008. They invest in index funds, but they are also more likely to also make self-directed investments than their parents or grandparents. Since 2008 the market has rewarded their participation. They aren’t expected to be investing like the generations before them. The new online tools and apps and zero commission structure, plus a wealth of information from online sources including Channelchek and others give them more confidence to make their own decisions.

 

 

The original idea behind indexing is that professional traders and actively managed funds will dictate how the market behaves, and take a small number of passive investors (e.g. index funds) along for the ride. But, here is where concern for what may happen on that ride comes into play. If you’re visual, think of it like this: Actively managed funds are a 60’ yacht. You’re an individual investor on a raft and decide to attach a line to the 60-footer to have it take you where it’s going. A free ride from someone who must know more based on the comparative power of your boats. The yacht is completely unchanged, course and speed are not impacted. This huge and small relationship was the original assumption behind passive investing. Market behavior is dictated by the active majority, and the passive minority gets a free ride.

What has happened since is more and more people have hooked their rafts to the back of the yacht to catch a ride, at some point there will be an impact to the maneuverability and economies of the yacht. As the passive riders outnumber the active managers, the free ride may fall apart.

We are now at the point where valuations in stocks are higher because they are in an index, and all the money in index funds has to compete for the same securities. We also see where stocks that are not in major indexes are not as highly valued because they get less attention. This two-class system isn’t healthy either.

 

Take-Away

The past 30-40 years have seen index funds grow to a height that has distorted valuations. One would think nothing can continue on indefinitely. The retirement or even death of baby boomers will put money that has been tied up in index funds in the hands of shopkeepers, grasscutters, and others they pay out of retirement funds. Upon death, some of this money will wind up in the hands of the next of kin and, in many cases, an entirely different account with different investment criteria. I picture an ACAT from the Vanguard 500 Index fund (VFIAX) into a more self-directed environment of a Robinhood account where the liquidated fund is reworked into Dogecoin (DOGE) and Gamestop (GME).

No one has an accurate crystal ball. This unintended consequence to index funds is worth paying attention to because it is a concern of professionals who have been very good at spotting trends – well in advance. If it does unfold, the younger generations may cause the unwinding of index funds as the go-to and replace it with directing their own stock picks.

 

Paul Hoffman

Channelchek, Managing Editor

 

Suggested Reading:

Should Investors Listen to Influencers?

Norton Crypto Debuts for Home Mining



Trading Accounts for Children

Do Microcap Stocks Provide Better Diversification?

 

Sources:

https://www.investopedia.com/articles/exchangetradedfunds/12/brief-history-exchange-traded-funds.asp

https://www.investopedia.com/articles/exchangetradedfunds/12/brief-history-exchange-traded-funds.asp#:~:text=The%20ETF%20Is%20Born,-According%20to%20Gary&text=The%20next%20attempt%20at%20the,Participation%20Units%20(TIPs%2035).

https://www.northwesternmutual.com/life-and-money/your-401k-when-it-was-invented-and-why/#:~:text=Despite%20their%20popularity%20today%2C%20401,being%20taxed%20on%20deferred%20compensation.

https://money.usnews.com/investing/funds/articles/do-index-funds-etfs-quietly-pose-a-systemic-risk-michael-burry-thinks-so

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

ACCO Brands Corporation Announces Participation in Noble Capital Markets’ Virtual Road Show Series

Posted on by Admin


ACCO Brands Corporation Announces Participation in Noble Capital Markets’ Virtual Road Show Series

 

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its management will participate in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek. The virtual road show will feature a presentation from Boris Elisman, ACCO Brands Chairman and Chief Executive Officer, followed by a Q&A session proctored by Noble Senior Research Analyst Joe Gomes, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for June 29, 2021, at 1 p.m. EDT. Registration is free and open to all investors. Register Here. The presentation also will be accessible through the Investor Relations section of www.accobrands.com or through Channelchek.com and will be archived on both websites following the event.

About ACCO Brands Corporation

ACCO Brands Corporation (NYSE: ACCO) is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include Artline®, AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, Quartet®, PowerA®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones® and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

Christine Hanneman
Investor Relations
(847) 796-4320

Julie McEwan
Media Relations
(937) 974-8162

Source: ACCO Brands Corporation

Release – Genprex Announces Initiation of its Phase 1 2 Acclaim-1 Clinical Trial for REQORSA Immunogene Therapy

Posted on by Admin


Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

 

AUSTIN, Texas — (June 23, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Company’s clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with AstraZeneca’s Tagrisso® in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. In January 2020, Genprex received FDA Fast Track Designation for the Acclaim-1 patient population.

In addition, the Company has engaged its first clinical site for Acclaim-1, and Genprex is continuing to work with a number of other important cancer research centers and academic institutions to select optimal study sites.

“This feedback from the FDA on our Acclaim-1 clinical trial and the engagement of our first clinical site are key milestones for Genprex,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We are now looking forward to opening patient enrollment in this important study of this cutting-edge investigational gene therapy to evaluate the role it can play in the fight against lung cancer, the leading cause of cancer deaths worldwide.”

The Company expects the Phase 1 portion of the Acclaim-1 trial to enroll up to 18 patients at three clinical sites and for the Phase 2 portion to enroll approximately 74 patients (a 1:1 ratio of REQORSA and Tagrisso combination therapy versus Tagrisso monotherapy) at up to 15 clinical sites. The first part of the Phase 1/2 clinical trial will be a dose escalation study. The primary endpoint of the Phase 2 portion of the trial is progression-free survival, which is defined as time from randomization after first progression on Tagrisso, to first event (second progression) or death. An interim analysis will be performed at 51 events.

Genprex recently announced the Centralized Institutional Review Board (IRB) approval for the Acclaim-1 clinical trial in NSCLC. Additional information about the Acclaim-1 clinical trial can be found by visiting ClinicalTrials.gov.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform for cancer. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

investors@genprex.com

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

media@genprex.com

electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China

Posted on by Admin


electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China

 

ROCKAWAY, NJ, 
June 23, 2021 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Kromax International Corporation to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in 
Taiwan and 
China.

“Kromax International Corp. is dedicated to transforming healthcare quality by introducing state-of-art medical solutions that improve the health of patients,” commented  Tim Hwang, 
Kromax Group Vice Chairman. “We have been deeply involved in the field of pain management and neuromodulation in the 
Taiwan, 
China, and 
South Asia markets for many years and are honored to cooperate with electroCore by representing their solution in these markets, providing benefits to patients in our region suffering from migraines.”

“We are delighted to partner with Kromax to introduce gammaCore into 
Taiwan and China,” stated Iain Strickland, electroCore’s Vice President of Global Sales and Strategy. “Kromax and electroCore share the common goal of utilizing proven healthcare innovations to improve the health and lives of their patients. We look forward to collaborating with the team at Kromax to help support the adoption of gammaCore in the region.”

The initial term of the agreement is three years, and it contains customary terms and conditions. Regulatory clearances are required before sales and revenue can occur, and the timing for any such potential clearances is uncertain at this time.

        
About Kromax

Founded in 1987, Kromax provides services covering the semiconductor, LCD, LED, solar and biotech industries in the 
Greater China area. Their business philosophy focuses on providing comprehensive services to the customer, starting from the early stages of research and marketing and also touching sales, production, distribution, installation, and warranty support. Their mission is to continually enhance the ability of our customers to compete in the international marketplace by bringing them the latest, most advanced technology.

For more information, visit www.kromax.com/en-US/AboutKromax.aspx

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients if they:
    • Have an active implantable medical device, such as pacemaker, hearing aid implant, or implanted electronic device
    • Have a metallic device such as a stent, bone plate, or bone screw, implanted at or near the neck
    • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric patients (less than 12 years of age)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in 
Taiwan, 
China, and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich CockrellCG Capital
404-736-3838
ecor@cg.capital

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com

Release – Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A

Posted on by Admin


Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

 

BOTHELL, Wash., June 23, 2021 — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021.

“We are highly encouraged by the potential of CC-42344 to treat seasonal and pandemic influenza, both of which are major global health concerns,” said Sam Lee, Ph.D., Cocrystal’s President and interim co-CEO. “We recently completed a 14-day GLP toxicology study, which was the final pre-IND enabling step prior to advancing this potent inhibitor into a first-in-human study.

“There is a pressing need for new antivirals to treat influenza, as currently approved antiviral therapeutics are prone to viral resistance,” added Dr. Lee. “CC-42344 stops the first step of viral replication by binding to a highly conserved PB2 site of the influenza polymerase complex that is essential to replication. This uniquely positions CC-42344 to be an effective therapeutic against all significant A strains of the influenza virus, including avian pandemic strains as well as strains that are resistant to Tamiflu® (oseltamivir) and Xofluza® (baloxavir marboxil).”

“The planned Phase 1 study with CC-42344 will be conducted in Australia, which offers favorable regulatory policies and a clinical trial environment that aligns with our strategy for quickly and cost-efficiently moving into clinical development,” said James Martin, Cocrystal’s CFO and interim co-CEO. “The Australian regulatory agency allows for a streamlined path for early-stage study initiation and the Australian government offers generous incentives for clinical studies performed in that country. Importantly, clinical studies conducted in Australia have a reputation for generating high-quality data. In preparing to initiate this study, we have already established a subsidiary in Australia and have selected a contract research organization.”

According to the World Health Organization (WHO) estimates, approximately 1 billion people are infected with seasonal influenza annually, resulting in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths worldwide. Approved influenza therapies have limited efficacy due to drug resistance and viral mutation.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy with respect to the clinical development of CC-42344, including the planned initiation of influenza A Phase 1 study in Australia in the third quarter of 2021, and the potential of CC-42344 to treat seasonal and pandemic influenza. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from the impact of the COVID-19 pandemic on the Australian and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Source: Cocrystal Pharma, Inc.

Release – Capstone Green Energy Secures Three New Rentals And Announces Expansion Of Its Rental Fleet

Posted on by Admin

 


Capstone Green Energy (Nasdaq:Cgrn) Secures Three New Rentals And Announces Expansion Of Its Rental Fleet, From 10.6 MW To 12.1 MW

 

Rented by an Oil & Gas Producer, Industrial Agricultural and Industrial Plastic Company

VAN NUYS, CA / ACCESSWIRE / June 23, 2021 / Capstone Green Energy Corporation(www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) formerly Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) (“Capstone” or the “Company”), announced today that it continues to expand its long-term microturbine rental business as part of its growing Energy as a Service (EaaS) business model, with an additional 1.1 megawatt (MW) of new long-term rental contracts. As a result, Capstone also announced today that it has expanded its low emission microturbine rental fleet from 10.6 MW to 12.1 MW.

The first of the new long-term rental contracts is a five-year rental agreement for a new C200 Signature Series slated for a local independent oil and gas producer focused on mature field revitalization, acquisitions, and exploration. The company optimizes and develops existing and acquired assets, and also implements thermal enhanced oil recovery and other technologies to expand existing oil production. This contract was secured by Capstone’s local distribution partner, Cal Microturbine, Capstone’s exclusive distributor for California, Hawaii, and Nevada and nonexclusive for Oregon and Washington (www.calmicroturbine.com).

The second long-term rental contract is a minimum five-month rental contract for a C800S for a new industrial agricultural operation. This rental agreement was secured by Capstone’s new Direct Solutions Sales organization. The five-month rental was pre-paid and was commissioned in mid-June.

The third rental contract is a one-year rental of a C65 for an industrial plastic company looking to utilize waste gas from a plastic recycling process. “If the C65 rental system operates satisfactorily on this off-spec gas, the customer has additional gas it’s not using at multiple other locations,” stated Jim Crouse, Capstone Green Energy, Chief Revenue Officer. “The rental program offers a unique and efficient method to test customer’s off-spec fuels that will allow us to determine applicability and durability in a fraction of the time it’s taken us in the past,” added Mr. Crouse.

Like Capstone Green Energy, all three customers are committed to health, safety, and environmental excellence. Leveraging Capstone Green Energy’s innovative microturbine technology will help all three companies save money and reduce their carbon footprint.

“Expanding Capstone’s Energy as a Service business, which includes the long-term rental program, is an important element for the Company achieving its strategic goals. Capstone is an eminent green energy company, having focused for a long time on transforming the way businesses think about on-site energy production,” said Darren Jamison, President and Chief Executive Officer of Capstone Green Energy.

“Growing our rental fleet is a key part of the business plan that we developed in conjunction with amending the Goldman Sachs Note Purchase Agreement on October 1, 2020, which includes the strategic expansion of the long-term rental fleet from 8.6 MW to 21.1 MW by March 2022,” said Eric Hencken, Chief Financial Officer of Capstone Green Energy. “Long-term rentals are a key to our future financial success as the recurring revenue stream they generate improves our gross margin and expense absorption,” concluded Mr. Hencken.

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy

Investment Opportunities in Hydrogen

Posted on by Admin


Unhyped Hydrogen Investments

 

Hydrogen finally seems on the road to fulfilling its “promise” of becoming a large contributor to the renewable energy mosaic. The interest in hydrogen energy was reignited last year with the push toward zero carbon emissions. Some other drivers of this elevated interest are increased government support and public interest in clean energy options. Hydrogen has been spoken about since the ’70s gas crisis as being the “answer.” It appears as though when it comes to lower emissions, power storage, and abundance, hydrogen is a prime candidate to be part of the answer.

There are many applications for hydrogen and hydrogen fuel cells, and as with most renewable energy solutions, there is some level of “baggage” that comes with each. We’ll discuss the baggage alongside the applications and provide the names of investable companies operating in and with the potential to benefit from the growth of hydrogen as a power source.

 

Powerful Applications for H

Processing Chemicals – Hydrogen’s primary use today is as a catalyst or agent in chemical and industrial processes. Among the chemical processes is the production of methanol and ammonia. The ammonia produced is used directly or indirectly as fertilizer. Hydrogen is also used to refine oil and as part of a process to remove impurities from crude oil. In steel production, it can be used to replace the traditional fuel (cokes) in a blast furnace. These processes are all currently being used and largely executed by what is called “dirty” or “grey” hydrogen.

 Automotive Fuel Cell– At the turn of the Millenium, hydrogen was going to be the clean-energy answer.   President George W. Bush even brought it up in his 2003 State of the Union address, saying, “the first car driven by a child born today could be powered by hydrogen and pollution-free.”

The unfilled expectations around hydrogen to power transportation have their reasons.  From a practical standpoint using a driver’s perspective, the shift would seem easy.  Fuelling a car with liquid H takes a similar amount of time as refilling with gas or diesel; the driving range would also be about the same. One issue preventing widespread use is the infrastructure for hydrogen refueling is not in place. And, as we have seen with electric vehicles, one can’t sell alternative “fuel” cars without the ability to fuel them along the road. On the other hand, building fuel stations isn’t economically feasible until there are customers. The solution to this chicken/egg question has yet to avail itself.

Heavy-Duty Transport– This category is comprised mainly of trains and boats. Hydrogen is a high-density energy source that can provide the appropriate power for heavy goods vehicles. It can provide power where we now implement diesel. Hydrogen is quick to refuel, which reduces downtime in these applications.

Forklifts– Fuel cells are already widely used in forklift fleets. One big advantage of hydrogen-powered fuel cells is it saves time compared to battery-powered machines. The benefits are particularly strong in a three-shift, round-the-clock operation. Fuel cells powered by hydrogen are also without carbon monoxide, which is preferable indoors. Large warehouses operated by Amazon and Walmart use hydrogen-powered forklift fleets.

Power Plants– Stationary Power plants are also using hydrogen fuel cells. They can be used as primary and backup power. The power is reliable and can support on-grid or off-grid power generation. These stationary fuel cells are able to connect directly to the gas infrastructure.

 

Grey Hydrogen vs. Green Hydrogen, What’s the Difference?

Hydrogen is as clean as the production method. Most hydrogen currently produced is called “dirty” or “grey” hydrogen. This means it was produced from natural gas and emits greenhouse gas. Grey hydrogen is produced using a process that isn’t the super clean hydrogen envisioned 20 or more years ago. That hydrogen, the one that emits no greenhouse gases, is referred to as “green” hydrogen. The difference provides a challenge and investment opportunities for this emerging field.  There is a lot of grey hydrogen used today that can be replaced by green hydrogen. It is estimated more than 95% of hydrogen production in 2019 was grey. Converting one to the other isn’t without cost, but it is then truly green.

Hydrogen can be produced using another method that is somewhat cleaner than grey. It uses natural gas and is called steam reforming. With steam reforming, it’s possible to capture 80% to 90% of the CO2 produced in the process. This CO2 is then used in other processes. You’ll hear hydrogen separated in this way called “blue” hydrogen. An alternative natural gas technique that doesn’t generate CO2 creates “turquoise” hydrogen.

 

Investments In Hydrogen

 There are many companies worldwide in this space.  The largest companies are hydrogen producers, which mainly use the method of steam reforming. Smaller niche companies focus on specific aspects of hydrogen. These can be sub-categorized into electrolyzer producers and fuel cell producers. Some companies will combine the two providing a fully integrated hydrogen producer.

There is a movement toward green hydrogen for most involved. This movement includes joint ventures, sometimes the small helping the big. Linde (LIN), for example, has a joint venture with ITM Power (OTCPK:ITMPF). ITM Linde Electrolysis provides industrial-scale turnkey solutions for green hydrogen production.

 

Electrolyzers

Electrolyzers are one way to invest in green hydrogen. There is a lot of wind, and solar-produced energy coming onto the power grid. One problem with this is the unstable production associated with these methods. By transforming this energy into green hydrogen, it can replace the current supply of grey hydrogen. electrolyzers may be the best way to invest in hydrogen.

Electrolyzers use a system that, with the use of electricity, breakdown water (H2O) into hydrogen and oxygen in a process known as electrolysis. McPhy Energy SA (OTC:MPHYF) is a designer, manufacturer, and integrator of hydrogen equipment. Its product range features two main categories: Electrolyzers (hydrogen production equipment) of all capacities and hydrogen refueling stations (refueling/distribution equipment) for hydrogen-powered mobility. Another company, Nel Hydrogen (NLLSY) covers the entire chain from hydrogen production to the manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with fast fueling similar to conventional vehicles. The company’s segments include Fueling and Electrolyzer. ITM Power PLC (ITMPF) designs and manufactures integrated hydrogen energy systems for energy storage and clean fuel production.

The above companies are European with valuations that may cause concern in other industries. They are listed because they are pure-plays on green hydrogen and electrolysis.

SunHydrogen (OTCPK:
HYSR) could become an alternative to electrolyzer companies. SunHydrogen is working on an innovative hydrogen generator. The generator uses solar energy to split water into hydrogen and oxygen directly. The technology is still in the design and test stage.

 

Fuel Cell Companies

Fuel cells are necessary to convert hydrogen into electricity. They can be used in transportation or stationary power systems. Fuel cells can also be powered by other fuels such as natural gas. Most companies are focusing on fuel cells powered with hydrogen or flexible fuel cells. Ballard Power Systems (Nasdaq:BLDP) designs, develops, manufactures, sells, and services fuel cell products for a variety of applications, focusing on motive power (material handling and buses) and stationary power (backup power, supplemental power, and distributed generation). Fuel Cell Energy ((Nasdaq:FCEL) designs manufactures, sells, installs, operates, and services fuel-cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as wastewater treatment, commercial and hospitality, data centers and communications, education and healthcare, and others. Plug Power (Nasdaq:PLUG) just announced their plans to build a plant to create green hydrogen. The plant will produce 15 tons per day of liquid green hydrogen, produced using 100% renewable energy and intended to fuel transportation applications, including material handling and fuel cell electric vehicle fleets. Plug Power is investing $84 million in the facility, which is expected to create at least 24 jobs in the local community starting in 2022. Plug is an innovator of green hydrogen and fuel cell technology.

 

Conclusion

Wind, solar, nuclear, and other Renewables are getting investors’ attention. Hydrogen has been spoken about for decades, but like electric vehicles, technology had to catch up with the desire to benefit from the potential. Globally, a move toward renewables is being supported by the major economies, closing the gap on the needed technology is now happening and ramp speed.

 

Suggested Reading:

How Does the Gates Buffett Natrium Reactor Works?

Is the Future of Nuclear, Small Modular Reactors?



What Companies are Involved in Spaceflight?

The Future of Electric Vehicles

 

Sources:

https://www.fchea.org/stationary

https://safety4sea.com/seven-energy-and-maritime-companies-collaborate-on-hydrogen/

https://www.iea.org/data-and-statistics/data-products

https://www.iea.org/fuels-and-technologies/hydrogen

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Harte Hanks Promotes Brian Linscott to Chief Executive Officer

Posted on by Admin


Harte Hanks Promotes Brian Linscott to Chief Executive Officer

 

Linscott’s Two-year Plus Company Senior Executive Role Ensures Continuity of Experienced Leadership

 

AUSTIN, Texas, 
June 23, 2021 /PRNewswire/ — 
Harte Hanks, Inc. (OTCQX: HRTH), an industry leader 
in Marketing Services and Execution, Customer Care, Fulfillment and Logistics Services, today announced that its Board of Directors has promoted Chief Operating Officer Brian Linscott to the position of CEO, succeeding Andrew Benett, effective immediately.

Mr. Benett is stepping down from his role as Chief Executive Officer to pursue other opportunities after positioning 
Harte Hanks for ongoing success.  Mr. Linscott and  Mr. Benett have agreed to work together to ensure a smooth transition at the Company.

Jack Griffin, Chairman of the Board of 
Harte Hanks, stated, ” Mr. Benett and  Mr. Linscott have worked closely together over the past 18 months and this transition ensures continuity of seasoned leadership at Harte Hanks. Brian’s success at 
Harte Hanks and his two plus decades of experience in operations, growth strategies, acquisitions, and finance, as well as leading teams in the development of new client opportunities positions Brian perfectly to lead Harte Hanks as our new CEO in our next phase of profitable growth.”

Mr. Linscott added, “We have worked to structure Harte Hanks for growth and profitability as our clients get back to business. I am honored to lead 
Harte Hanks’ outstanding team at this exciting time as we enter the next phases of this post-pandemic world.”

Brian has an accomplished track record for improving financial and operational results. Before joining 
Harte Hanks in late 2019, his prior positions include CFO of 
Sun Times Media, LLC, a media company that included the Chicago Sun-Times, Managing Director of Huron Consulting Group, and a Partner at 
BR Advisors, where he led operational improvements, developed new partnerships and drove topline growth for media clients and other companies.

Mr. Griffin continued, “I want to thank Andrew for his hard work and dedication in leading the Company through the challenges of restructuring our organization during the COVID-19 pandemic as well as maintaining the confidence and loyalty of our clients.”  

“I am proud of the progress we have achieved at 
Harte Hanks, and it has been a pleasure building and leading such a strong team,” said  Andrew Benett. “Brian is an accomplished corporate executive, and I am confident that he has the skills to lead execution at 
Harte Hanks going forward.”

About Harte Hanks 

Harte Hanks is a global marketing services firm specializing in customer lifecycle management.  
Harte Hanks effectively connects our clients with their customers in powerful ways. We are experts in defining, executing and optimizing the customer journey by offering end-to-end BPO marketing services including lead generation, data analytics, and multi-channel customer engagement solutions (digital, social, and mobile), as well as contact center, fulfillment and logistics services. From visionary thinking to tactical execution, Harte Hanks delivers smarter customer interactions for some of the world’s leading brands. Harte Hanks has approximately 2,500 employees located in North America, Asia-Pacific and Europe.

Cautionary Note Regarding Forward-Looking Statements:

Our press release and related earnings conference call contain “forward-looking statements” within the meaning of 
U.S. federal securities laws. All such statements are qualified by this cautionary note, provided pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements other than historical facts are forward-looking and may be identified by words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “seeks,” “could,” “intends,” or words of similar meaning.  These forward-looking statements are based on current information, expectations and estimates and involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.  In that event, our business, financial condition, results of operations or liquidity could be materially adversely affected and investors in our securities could lose part or all of their investments.  These risks, uncertainties, assumptions and other factors include: (a) local, national and international economic and business conditions, including (i) the outbreak of diseases, such as the COVID-19 coronavirus, which has curtailed travel to and from certain countries and geographic regions, disrupted business operations resulting from travel restrictions and reduced consumer spending, and uncertainty regarding the duration of the virus’ impact, (ii) market conditions that may adversely impact marketing expenditures and (iii) the impact of economic environments and competitive pressures on the financial condition, marketing expenditures and activities of our clients and prospects; (b) the demand for our products and services by clients and prospective clients, including (i) the willingness of existing clients to maintain or increase their spending on products and services that are or remain profitable for us, and (ii) our ability to predict changes in client needs and preferences; (c) economic and other business factors that impact the industry verticals we serve, including competition and consolidation of current and prospective clients, vendors and partners in these verticals; (d) our ability to manage and timely adjust our facilities, capacity, workforce and cost structure to effectively serve our clients; (e) our ability to improve our processes and to provide new products and services in a timely and cost-effective manner though development, license, partnership or acquisition; (f) our ability to protect our facilities against security breaches and other interruptions and to protect sensitive personal information of our clients and their customers; (g) our ability to respond to increasing concern, regulation and legal action over consumer privacy issues, including changing requirements for collection, processing and use of information; (h) the impact of privacy and other regulations, including restrictions on unsolicited marketing communications and other consumer protection laws; (i) fluctuations in fuel prices, paper prices, postal rates and postal delivery schedules; (j) the number of shares, if any, that we may repurchase in connection with our repurchase program; (k) unanticipated developments regarding litigation or other contingent liabilities; (l) our ability to complete anticipated divestitures and reorganizations, including cost-saving initiatives; (m) our ability to realize the expected tax refunds; and (n) other factors discussed from time to time in our filings with the 
Securities and Exchange Commission, including under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended 
December 31, 2020 which was filed on 
March 24, 2021. The forward-looking statements in this press release are made only as of the date hereof, and we undertake no obligation to update publicly any forward-looking statement, even if new information becomes available or other events occur in the future.

Contact: For more information, visit 
Harte Hanks at www.hartehanks.com, call 800-456-9748, or email us at pr@hartehanks.com and/ or sbe@abmac.com.

SOURCE: 
Harte Hanks

Esports Entertainment Group Named Official Esports Tournament Provider of the New York Rangers

Posted on by Admin

 


Esports Entertainment Group Named Official Esports Tournament Provider of the New York Rangers

 

Esports Gaming League will Host Three Rangers-Themed Esports Tournaments

NEW YORK–()–The New York Rangers announced today a marketing partnership with Esports Entertainment Group Inc. (EEG), naming the esports company their Official esports tournament provider, beginning on July 1. As part of this relationship, EEG will operate three Rangers-themed esports tournaments utilizing its Esports Gaming League brand and platform. EEG will work with the Rangers organization to create custom videos that promote these tournaments across all Rangers digital platforms. Each tournament will include incredible prizes such as Rangers merchandise and memorabilia.

“Over the last few years, we’ve hosted dozens of amateur esports tournaments with our esports organization CLG, which have been incredibly well received and we can’t wait to expand on this with the Rangers,” said Dan Fleeter, Vice President, Business Operations, MSG Sports Corp. “We look forward to a long and mutually rewarding relationship with EEG and believe this is a wonderful opportunity to engage with an audience interested in hockey and gaming.”

Esports Gaming League enables live and online events and tournaments where gamers can compete and enjoy a wide range of content relating to esports and video games on a proprietary technology platform. Services include full turnkey esports events, live broadcast production, game launches, and online branded tournaments.

“We are thrilled to welcome another leading professional sports team to our tournament platform,” said Grant Johnson, CEO of Esports Entertainment Group. “We look forward to working with the Rangers as they extend their brand into the rapidly growing world of esports.”

“We are quickly becoming the industry standard tournament platform for professional sports, as teams recognize the strength of our platform and its ability to meet the demanding needs of large-scale deployments,” said Magnus Leppäniemi, President of Esports at Esports Entertainment Group. “We look forward to helping the Rangers achieve their goals in this exciting new arena.”

Madison Square Garden Sports Corp.

Madison Square Garden Sports Corp. (MSG Sports) is a leading professional sports company, with a collection of assets that includes: the New York Knicks (NBA) and the New York Rangers (NHL); two development league teams – the Westchester Knicks (NBAGL) and the Hartford Wolf Pack (AHL); and esports teams through Counter Logic Gaming, a leading North American esports organization, and Knicks Gaming, an NBA 2K League franchise. MSG Sports also operates two professional sports team performance centers – the MSG Training Center in Greenburgh, NY and the CLG Performance Center in Los Angeles, CA. More information is available at www.msgsports.com.

About Esports Entertainment Group

Esports Entertainment Group, Inc. is an esports and iGaming company. The Company maintains offices in New Jersey, the UK and Malta. For more information, visit: www.esportsentertainmentgroup.com

Contacts

MEDIA CONTACTS:
Madison Square Garden Sports:
Ryan.Watson@msgsports.com

Esports Entertainment Group:
jeff@esportsentertainmentgroup.com